ESRD

Global Dialysis Market Set for Impressive Growth, Projected to Reach US$107.96 Billion by 2023 with a Strong CAGR of 4.80% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 25, 2023
Health, Medical Devices, Diabetes, Hospitals, Managed Care, General Health, Biotechnology, Kidney, Waste, Incidence, Kidney failure, Equipment, Prevalence, Co-production (public services), Chronic kidney disease, Dialysis, Growth, COVID-19, Blood, Kidney disease, CKD, ESRD, Safety, Peritoneal dialysis, Video game, Medical device, Patient, Hemodialysis

The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.

Key Points: 
  • The global dialysis market is on track to achieve substantial growth, with projections indicating it will reach an impressive value of US$107.96 billion by 2023, supported by a robust CAGR of 4.80% over the forecast period.
  • The services segment currently holds the largest market share, while consumables are anticipated to exhibit the highest growth with a significant CAGR.
  • By Type: The global dialysis market is segmented into Hemodialysis and Peritoneal Dialysis.
  • The global dialysis market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Hemodialysis Dominates the Global Dialysis Market with Advanced Technology and Widespread Availability - ResearchAndMarkets.com

Retrieved on: 
Friday, October 13, 2023
Medical Devices, Health, Diabetes, Hospitals, Managed Care, Biotechnology, Dialysis, Kidney disease, Hospital, Hypertension, Investment, Chronic kidney disease, Research, ESRD, Prevalence, Risk, CKD, Creatinine, Kidney failure, Insurance, Ageing, Urea, Patient, Kidney transplantation, Blood, Waste, Pharmaceutical industry, Medical device, Growth

The global dialysis market is set to achieve remarkable growth, projected to exceed $141.26 billion by 2028, according to Renub Research.

Key Points: 
  • The global dialysis market is set to achieve remarkable growth, projected to exceed $141.26 billion by 2028, according to Renub Research.
  • Chronic kidney disease (CKD) is a progressive condition affecting over 10% of the global population, totaling more than 800 million individuals.
  • The global prevalence of diabetes among people aged 20-79 was 11% in 2021, expected to rise to 12% by 2045.
  • Additionally, Chinese companies have made significant strides in manufacturing dialysis equipment, contributing to both domestic supply and global export.

Peripheral Vascular Repair Segment Leads Robust Growth in the Vascular Grafts Market with 8.9% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Medical Supplies, Health, Medical Devices, Hospitals, Surgery, Cardiology, Biotechnology, Dialysis, Stroke, Peritoneal dialysis, Fatality, Cardiovascular disease, ESRD, Patient, Type, Medical device

Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others

Key Points: 
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    Global Population of ESRD Patients Undergoing Therapy by Type of Treatment (2020): Percentage Breakdown of Patients Receiving Hemodialysis, Kidney Transplants, and Peritoneal Dialysis
    Global Dialysis Market by Region: Percentage Breakdown of Patients Receiving Dialysis Treatment in In-Centre and Home Settings for 2019
    Global Middle Class Population (in Millions) and as a Percentage of Total Population: 2005, 2015, 2025 & 2035
    Some of the important vascular innovations expected in the near-term include:

American Regent Introduces Levocarnitine Injection, USP; FDA-Approved, "AP" Rated, and Therapeutically Equivalent to Carnitor®¹

Retrieved on: 
Tuesday, October 10, 2023
Urine, INR, Kidney disease, ESRD, Vomiting, Carnitine, Milk, Nursing, Safety, Pregnancy, Edema, Dialysis, Nausea, FDA, Warfarin, Drinking fountain, Gastritis, Child, Seizure, Anaphylaxis, Patient, Vaccine, Pharmaceutical industry, Dietary supplement

Consider the risks and benefits of re-administering levocarnitine to individual patients following a severe reaction.

Key Points: 
  • Consider the risks and benefits of re-administering levocarnitine to individual patients following a severe reaction.
  • Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

Neway Forms Lab Services Agreement with Quest Diagnostics to Speed Quality ESRD Testing

Retrieved on: 
Thursday, October 5, 2023
Cleveland, Multimedia, NYSE, Doctor of Philosophy, Quest Diagnostics, Quest, Kidney disease, ESRD, Insurance, Transport, Dialysis, DGX, Patient, Atmosphere, Medical device, Newai

LITTLETON, Colo., Oct. 5, 2023 /PRNewswire/ -- Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD).

Key Points: 
  • LITTLETON, Colo., Oct. 5, 2023 /PRNewswire/ -- Neway, LLC, the U.S. leader in value-based dialysis lab care, today announced a strategic lab services arrangement with Quest Diagnostics (NYSE: DGX) that aims to accelerate dialysis laboratory testing and reduce the laboratory costs of dialysis programs for patients with end-stage renal disease (ESRD).
  • Under the terms of the agreement, Neway will utilize the extensive lab network of Quest Diagnostics to provide local dialysis laboratory testing services with typically next-day results after arrival at a Quest Diagnostics laboratory.
  • By utilizing Quest's distributed lab network, Neway and its affiliated dialysis centers and their patients will experience faster testing and results reporting and lower transportation costs.
  • "Working together with Neway, we will address these challenges and expedite test results while maintaining the highest level of quality for patients with ESRD."

Rimidi to Showcase New Chronic Kidney Disease Module at HLTH 2023, Complementing Suite of Chronic Disease Management Solutions

Retrieved on: 
Tuesday, October 3, 2023
Kidney disease, ESRD, Kidney failure, Chronic kidney disease, Diabetes, Electronic health record, Workflow, Risk, Doctor of Philosophy, KFRE, Dialysis, Hypertension, Triage, Module, MD, EHR, Patient, Death, CKD, Conditional sentence, Nursing, Pharmaceutical industry, Medical imaging

ATLANTA, Oct. 3, 2023 /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences, and achieve quality objectives for chronic disease management, today announced the launch of its new Chronic Kidney Disease (CKD) Module, designed to give providers better visibility on the status of their population of patients with CKD to improve disease management.

Key Points: 
  • Given that Rimidi already supports disease management and remote patient monitoring for diabetes and hypertension, two common risk factors for CKD, developing a full CKD Module was a natural platform progression.
  • Similar to Rimidi's additional chronic disease modules , the CKD Module will combine clinically relevant data from the Electronic Health Record (EHR) with patient-generated data from connected devices and patient surveys into a streamlined, problem-oriented view that allows for better risk stratification and chronic disease management.
  • The KFRE predicts the 5-year risk of end-stage renal disease (ESRD) in patients with chronic kidney disease (CKD) stages 3-5.
  • For more information about Rimidi's Chronic Kidney Disease Module, visit rimidi.com/chronic-kidney-disease or stop by booth #853 at HLTH 2023.

Growth Potential in Hemodialysis Vascular Grafts Market Foreseen with Key Trends and Insights (2023-2030) - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Biotechnology, Health, Medical Devices, Well, ESRD, Telehealth, Polytetrafluoroethylene, Vein, COVID-19, Kidney disease, Research, Artery, USD, Government, Dialysis, Incidence, Chronic condition, Patient, Investment, PTFE, Growth, Chronic kidney disease, CKD, Pharmaceutical industry

The global hemodialysis vascular grafts market is set to expand at a CAGR of 5.1% between 2023 and 2030.

Key Points: 
  • The global hemodialysis vascular grafts market is set to expand at a CAGR of 5.1% between 2023 and 2030.
  • COVID-19 catalyzed the adoption of telemedicine, potentially boosting the demand for hemodialysis vascular grafts as more patients gain remote access to treatment.
  • The " Hemodialysis Vascular Grafts Market Size, Share & Trends Analysis Report ," sheds light on the significant potential of the hemodialysis vascular grafts sector.
  • Key Players in the Market:
    Noteworthy companies in the hemodialysis vascular grafts market include:

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

Retrieved on: 
Wednesday, September 27, 2023
Kidney disease, ESRD, US Foods, IR, Chronic kidney disease, PBC, ODD, Cochlea, SCCHN, Head, Alport syndrome, Neck, Trial of the century, Hypertension, Proteinuria, Internet, Primary biliary cholangitis, Sustainability, Genetic disorder, Patient, Huber loss, CALT, FDA, SA, IPF, CKD, Gene, Idiopathic pulmonary fibrosis, Food, Pharmaceutical industry, Satellite navigation device, GFR, Alport

STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.

Key Points: 
  • STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.
  • Based on supportive pre-clinical work, Calliditas plans to initiate a randomized, placebo-controlled phase 2 clinical study in Alport syndrome with around 20 patients in the fourth quarter of 2023.
  • "We are excited to start another clinical program in the renal space targeting an orphan indication where today there are no approved products," said CEO Renée Aguiar-Lucander.
  • Alport syndrome is a genetic disorder arising from the mutations in the genes that code for type 4 collagen.

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

Retrieved on: 
Wednesday, September 27, 2023
Kidney disease, ESRD, US Foods, IR, Chronic kidney disease, PBC, ODD, Cochlea, SCCHN, Head, Alport syndrome, Neck, Trial of the century, Hypertension, Proteinuria, Internet, Primary biliary cholangitis, Sustainability, Genetic disorder, Patient, Huber loss, CALT, FDA, SA, IPF, CKD, Gene, Idiopathic pulmonary fibrosis, Food, Pharmaceutical industry, Satellite navigation device, GFR, Alport

STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.

Key Points: 
  • STOCKHOLM, Sept. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the company for the treatment of Alport syndrome with setanaxib.
  • Based on supportive pre-clinical work, Calliditas plans to initiate a randomized, placebo-controlled phase 2 clinical study in Alport syndrome with around 20 patients in the fourth quarter of 2023.
  • "We are excited to start another clinical program in the renal space targeting an orphan indication where today there are no approved products," said CEO Renée Aguiar-Lucander.
  • Alport syndrome is a genetic disorder arising from the mutations in the genes that code for type 4 collagen.

Florida Dialysis Centers Market Size, Share & Trends Analysis Report 2023: A $1.3 Billion Market by 2030 - Escalating Demand for Dialysis Units Propelling Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Medical Devices, Health, Arteriovenous, ESRD, American Kidney Fund, Prevalence, Kidney, COVID-19, Research, History, Hemodialysis, USD, Dialysis, Medicare, Hospital, Peritoneal dialysis, Investment, Patient, DaVita Inc., Growth, Chronic kidney disease, CKD, SNF, Fistula, Medical device, Pharmaceutical industry

The "Florida Dialysis Centers Market Size, Share & Trends Analysis Report By Modality (In-Center, In-Home, SNF-based), By Dialysis Type (Hemodialysis, Peritoneal Dialysis), By Facility Type, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Florida Dialysis Centers Market Size, Share & Trends Analysis Report By Modality (In-Center, In-Home, SNF-based), By Dialysis Type (Hemodialysis, Peritoneal Dialysis), By Facility Type, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • According to the American Kidney Fund, Florida is home to approximately 48,215 individuals grappling with End-Stage Renal Disease (ESRD).
  • The escalating demand for dialysis units across the state of Florida emerges as a pivotal factor expected to propel market growth in the coming years.
  • As of April 2023, DaVita owns or manages more than 200 outpatient dialysis centers in Florida